Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine headlines to help you catch up and stay informed. It was a busy week with lots of news, have a look and see you next week for another update.
Atai Announces Positive Phase 1 Results for Opioid Use Disorder
Atai has announced positive initial results for their Phase 1 clinical trial of KUR-101:
- Initial results showed that single ascending oral dosing of KUR-101 produces dose-dependent analgesia (pain relief) with effects on respiration comparable to that of placebo.
- Topline results, including Part 2 comparing a single dose of KUR-101 to a single dose of oxycodone or placebo, are expected by the end of 2022.
- KUR-101 is an oral formulation of deuterated mitragynine, the major active alkaloid of the kratom plant, under development for the treatment of opioid use disorder (OUD).
Small Pharma Reports Fiscal Second Quarter 2023 Highlights
George Tziras, Chief Executive Officer of Small Pharma: “Over the summer months our team has made significant progress across our pipeline of short-acting psychedelic-assisted therapies, with a focus on progressing new trials into the clinic and expanding our IP portfolio, including a key U.S. patent grant.
“We continue to expand our SPL026 clinical program with the initiation of a SSRI drug interaction study and regulatory approval for a further Phase I trial. We are also approaching a key milestone: the completion of our SPL026 Phase IIa clinical trial in patients with MDD. Dosing is now complete and we eagerly await the results to learn more about the potential efficacy of short-acting psychedelics in treating MDD.”
Palo Santo Closes $50 Million Psychedelic Investment Fund
The Palo Santo Fund is currently invested in over 20 portfolio companies across the psychedelic ecosystem, including Beckley Psytech, Tactogen, Bexson Biomedical, Ksana Health, Gilgamesh Pharmaceuticals, Delix Therapeutics, Journey Clinical, and Fluence, among others. Palo Santo combines its investing and portfolio building experience with the expertise of leading academics and advisors in psychedelic science.
Lobe Sciences Announces the Completion of cGMP Production of Clinical Supplies For Upcoming Clinical Trials
Philip J. Young, Chairman and Chief Executive Officer of the Company stated, “This is an important step and validation of our approach to developing novel psilocin analogues to treat severe forms of anxiety, including a pediatric orphan indication. Our manufacturing partner has produced sufficient quantities of L-130 to dose subjects and patients in our first two Phase 1 programs. Ongoing stability and quality programs are in place to allow the use of all of the data generated in these studies to support our Investigational New Drug Application (IND) planned for early next year.”
Silo Wellness Closes Acquisition of Dyscovry Science and Its Psilocybin Pharmaceutical Biosynthesis and Research Portfolio
“Bringing the Dyscovry team into the Silo Wellness family is a key component to our pharmaceutical vision which began with our July 2019 priority date for our patent-pending metered-dosing modalities for psilocybin, mescaline, DMT, and 5-MeO-DMT,” stated Silo Wellness founder and CEO Mike Arnold, an Oregon attorney.
“With our presence and founding in Oregon along with our psychedelic retreat operational experience in Jamaica [with psilocybin and 5-MeO-DMT] and Oregon [with ketamine], Dyscovry’s portfolio will allow us to further our goal of covering both tracks of the psychedelic industry under one roof: psychedelic healing now via jurisdiction-by-jurisdiction “adult use” and pharmaceutical biotech.”
